TSX gains after CPI shows US inflation rose 3%
Investing.com -- Stifel has resumed coverage of several medtech companies, citing steady adoption of continuous glucose monitors (CGMs) and insulin pumps as key drivers for growth.
The firm rated DexCom (NASDAQ: DXCM) and Insulet (NASDAQ: PODD) as Buys, while maintaining Hold ratings on Senseonics (NYSE: SENS) and Tandem (NASDAQ: TNDM).
“Our diligence is upbeat for the Continuous Glucose Monitor market as it identifies long-term opportunities in the large T2 Basal-only and T2 Non-insulin markets,” Stifel wrote.
The firm said DexCom’s “15-day sensor was the standout among CGM innovations” and that “investors’ perceived G7 issues are not top of mind among Endocrinologists or PCPs.”
Stifel resumed coverage of DexCom with a Buy rating and $85 price target.
For Senseonics, Stifel noted that “Eversense 365-day prescribers are expected to step up solidly over the next twelve months,” but said traction may “take time and additional capital.” The firm resumed coverage of the stock with a Hold rating and $9 target.
In the insulin pump segment, Stifel said its diligence “suggests the T2 Insulin-intensive opportunity has legs for pump providers and that the patch is the preferred form factor.”
The firm added that these factors “play to Insulet’s strengths,” resuming coverage with a Buy rating.
Stifel also cited growing physician interest in Beta Bionics’ (NASDAQ: BBNX) iLet system, calling it “a solid step up among prescribers in the T2 market.”
The firm rated Beta Bionics a Buy and Tandem a Hold, noting that “U.S. renewals may taper off into 2H26/2027” despite continued innovation in durable pumps.